{"id":61732,"date":"2025-08-15T10:05:42","date_gmt":"2025-08-15T08:05:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/"},"modified":"2025-08-15T10:05:42","modified_gmt":"2025-08-15T08:05:42","slug":"sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/","title":{"rendered":"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux"},"content":{"rendered":"
\n

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News:<\/p>\n

\nSensorion (FR0012596468 \u2013 ALSEN) <\/b>a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux.<\/p>\n

\nOn 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler Cheuvreux, modified by amendments dated 7 December 2018 and 15 July 2022 (the “Contract<\/b>“). This Contract aims to promote the liquidity of the Shares of Sensorion on Euronext Paris.<\/p>\n

\nOn 14 August 2025, in accordance with Article 4 of AMF Decision No. 2021-01 of 22 June 2021 renewing the establishment of liquidity contracts on equity securities as an accepted market practice, Sensorion increased the resources allocated to the liquidity contract by \u20ac60,000.<\/p>\n

\nFollowing this increase in resources, as of 14 August 2025, the following assets appear on the liquidity account:<\/p>\n

\n– 206,211 Sensorion Ordinary Shares
\n
– \u20ac66,965.21<\/p>\n

\nAbout Sensorion
\n
<\/b>Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
\n
It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1\/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
\n
Sensorion\u2019s portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion\u2019s small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.
\n
www.sensorion.com<\/a><\/p>\n

\nLabel: SENSORION
\n
<\/b>ISIN: FR0012596468
\n
<\/b>Mnemonic: ALSEN<\/b><\/p>\n

\nDisclaimer
\n
<\/b>This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations<\/b>
No\u00e9mie Djokovic, Investor Relations and Communication Associate
\n
ir.contact@sensorion-pharma.com<\/a><\/p>\n

Press Relations<\/b>
Ulysse Communication
\n
Bruno Arabian \/ 00 33(0)6 87 88 47 26
\n
barabian@ulysse-communication.com<\/a>
Nicolas Entz \/ 00 33 (0)6 33 67 31 54
\n
nentz@ulysse-communication.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux. On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61732","6":"format-standard","7":"category-industry"},"yoast_head":"\nSensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux. On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-15T08:05:42+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux\",\"datePublished\":\"2025-08-15T08:05:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/\"},\"wordCount\":643,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/\",\"name\":\"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2025-08-15T08:05:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/","og_locale":"en_US","og_type":"article","og_title":"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux - Pharma Trend","og_description":"MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: Sensorion (FR0012596468 \u2013 ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux. On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-15T08:05:42+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux","datePublished":"2025-08-15T08:05:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/"},"wordCount":643,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/","url":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/","name":"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2025-08-15T08:05:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sensorion-announces-an-increase-in-resources-allocated-to-the-liquidity-contract-with-kepler-cheuvreux\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61732"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61732\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}